Peer review reports
From: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
Original Submission |
10 Feb 2015 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
Resubmission - Version 5 |
|
Submitted |
Manuscript version 5
|
Resubmission - Version 6 |
|
Submitted |
Manuscript version 6
|
|
Reviewed |
Reviewer Report
|
|
Reviewed |
Reviewer Report
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 7 |
|
Submitted |
Manuscript version 7
|
|
Reviewed |
Reviewer Report
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 8 |
|
Submitted |
Manuscript version 8
|
Publishing |
7 Jul 2015 |
Editorially accepted |
|
29 Jul 2015 |
Article published |
10.1186/s12885-015-1534-0
|
Learn about peer review